China’s mRNA pioneer Stemirna faces post-Covid reinvention test
The biopharma company that led the way in Chinese mRNA research is battling a wave of lawsuits and financial woes, including court limits on its founder’s spending Key Takeaways: Flush…
FAST NEWS: JW Therapeutics to expand collaboration with 2Seventy Bio
The latest: Drug maker JW (Cayman) Therapeutics Co. Ltd. (2126.HK) said on Tuesday it is in talks to expand its strategic alliance with 2Seventy Bio (TSVT.US), which began with a partnership established in…
2126.HK
FAST NEWS: JW Therapeutics’ loss narrows on lower selling expenses
The latest: Biotech company JW (Cayman) Therapeutics Co. Ltd. (2126.HK) reported on Tuesday its net loss for the first half of 2023 narrowed 11.4% year-on-year to 380 million yuan ($52.1 million). Looking…
WuXi Biologics hatches new baby with ADC drug unit IPO
The drug outsourcing services company is spinning off its WuXi XDC unit, seizing on investor enthusiasm for a new generation of highly targeted ADC drugs Key Takeaways: WuXi XDC has…
2269.HK
FAST NEWS: U.S. investment firm boosts WuXi AppTec stake
The latest: The Capital Group, a U.S. asset manager, disclosed it purchase 2.52 million Hong Kong-listed shares of WuXi AppTec Co. Ltd. (2359.HK; 603259.SH) for HK$177 million ($20.8 million), raising…
2359.HK
603259.SHG
Wuxi AppTec finds bitter aftertaste in waning demand for Covid drug services
The leading Chinese CXO posted record revenue and strong profits last year, but its growth started to slow in the fourth quarter Key Takeaways: Wuxi AppTec’s chemical business doubled last…
2359.HK
603259.SHG
After 2022 Slowdown, WuXi Biologics Gets Growth Medicine From Big New Order
China’s leading provider of outsourced medical services said its profit and revenue rose 48.4% and 30% last year, respectively, marking a significant slowdown from the previous yearKey Takeaways:WuXi Biologics revenue…
Recent Articles
FAST NEWS: U.S. investment firm boosts WuXi AppTec stake
2359.HK
603259.SHG
Wuxi AppTec finds bitter aftertaste in waning demand for Covid drug services
2359.HK
603259.SHG
